|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
DE69534265T2
(de)
|
1994-12-12 |
2006-05-04 |
Beth Israel Deaconess Medical Center, Inc., Boston |
Chimäre zytokine und ihre verwendung
|
|
AU6455896A
(en)
|
1995-07-11 |
1997-02-10 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
WO1997040145A1
(en)
|
1996-04-24 |
1997-10-30 |
The Regents Of The University Of Michigan |
Inactivation resistant factor viii
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US6593294B1
(en)
|
1998-04-27 |
2003-07-15 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising Factor VIII and neutral liposomes
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
JP2005518181A
(ja)
|
2001-01-12 |
2005-06-23 |
ジ・アメリカン・ナショナル・レッド・クロス |
第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
|
|
ES2331909T3
(es)
|
2001-06-14 |
2010-01-20 |
The Scripps Research Institute |
Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
|
|
AU2003210806A1
(en)
|
2002-03-05 |
2003-09-22 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
AU2003227687B2
(en)
|
2002-04-29 |
2009-10-15 |
Stichting Sanquin Bloedvoorziening |
Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
BRPI0407882B1
(pt)
|
2003-02-26 |
2021-07-27 |
Nektar Therapeutics |
Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
|
|
PL2298347T3
(pl)
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
DK1641823T3
(da)
|
2003-06-12 |
2011-12-12 |
Lilly Co Eli |
GLP-1-analog fusionsproteiner
|
|
RU2370276C2
(ru)
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
PT2363414T
(pt)
|
2004-11-12 |
2022-08-04 |
Bayer Healthcare Llc |
Modificação de fviii direcionada a sítio
|
|
CN101163506B
(zh)
|
2004-12-27 |
2012-09-26 |
巴克斯特国际公司 |
聚合物-von Willebrand因子偶联物
|
|
KR20080007226A
(ko)
|
2005-04-14 |
2008-01-17 |
체에스엘 베링 게엠베하 |
증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
AU2007245190B2
(en)
|
2006-03-31 |
2011-07-21 |
Takeda Pharmaceutical Company Limited |
Pegylated factor VIII
|
|
EP2032607B2
(en)
|
2006-06-14 |
2017-02-22 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
CA2673459C
(en)
|
2006-12-22 |
2016-09-13 |
Stefan Schulte |
Modified coagulation factors with prolonged in vivo half-life
|
|
PL2291523T3
(pl)
|
2008-06-24 |
2015-05-29 |
Csl Behring Gmbh |
Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
|
|
WO2011060242A2
(en)
*
|
2009-11-13 |
2011-05-19 |
Talecris Biotherapeutics, Inc. |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
|
WO2013120939A1
(en)
|
2012-02-15 |
2013-08-22 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
|
JP2015515482A
(ja)
|
2012-04-24 |
2015-05-28 |
ノヴォ ノルディスク アー／エス |
血友病の治療に適する化合物
|
|
CN104661674A
(zh)
|
2012-07-11 |
2015-05-27 |
阿穆尼克斯运营公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
EP2796145B1
(en)
*
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
|
CN105452289A
(zh)
|
2013-06-12 |
2016-03-30 |
诺和诺德股份有限公司 |
适用于治疗血友病的化合物
|
|
CN113817069A
(zh)
*
|
2013-06-28 |
2021-12-21 |
比奥贝拉蒂治疗公司 |
具有xten的凝血酶可裂解连接子和其用途
|
|
BR112016030950A2
(pt)
*
|
2014-07-02 |
2018-03-27 |
Csl Ltd |
polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
|
|
JP6651548B2
(ja)
*
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォン・ヴィルブランド因子を製造するための方法
|
|
EP3297656B1
(en)
*
|
2015-05-22 |
2020-01-08 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
DK3400002T3
(da)
*
|
2016-01-07 |
2022-04-11 |
CSL Behring Lengnau AG |
Muteret, trunkeret von willebrand faktor
|
|
RU2018128613A
(ru)
*
|
2016-01-07 |
2020-02-07 |
Цсл Беринг Ленгнау Аг |
Мутированный фактор фон виллебранда
|